The development of tyrosine kinase inhibitors (TKIs), such as imatinib, inhibiting the activity of the BCR-ABL1 tyrosine kinase, represented a significant breakthrough in CML treatment. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.